Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Type 2 diabetes

SGLT-2 inhibitors: a new oral therapy option

    • Congress Reports
    • Endocrinology and Diabetology
    • Partner Content
    • RX
  • 3 minute read

Dapagliflozin, a potent new selective SGLT-2 inhibitor, is available in many countries for use in type 2 diabetes patients either as add-on combination therapy when other glucose-lowering medical agents together with exercise and diet have failed to provide adequate glycemic control, or as monotherapy in metformin intolerance. A satellite symposium at the ESCIM Congress in Geneva focused on the efficacy and safety of this substance.

(ag) According to Prof. Clifford Bailey, MD, Birmingham, progressive type 2 diabetes typically requires different therapies, but these are limited when complications arise. Such can be reduced mainly by good glucose control. The etiology is also multivariable, heterogeneous, and just progressive. “While we already have effective therapies available for several key organs that play a role in the regulation of plasma glucose, the kidney has been missing until now. This produces about 20% of the total glucose in the body and uses almost all of it itself. In addition, it filters about 180 g of glucose per day, of which it also reabsorbs almost all. It is therefore an important player in the entire glucose process. In type 2 diabetes, the kidney is now working overtime,” Prof. Bailey explained. The absorption occurs mainly via the so-called “sodium glucose cotransporter-2” (SGLT-2). If this is now inhibited (Fig. 1), as is possible with the new selective SGLT-2 inhibitor dapagliflozin, the excretion of glucose via the urine increases (glucosuria).

 

“This reduces plasma glucose, addresses hyperglycemia, and supports weight loss. The likelihood of hypoglycemia is comparable to placebo. All of this is completely insulin-independent. So, unlike other therapies, an effect can still be achieved when insulin secretion decreases,” says the expert [1].
In addition, SGLT-1 inhibition also delays intestinal glucose absorption. Various such substances are currently being clinically tested.

How does dapagliflozin fit into the overall concept of therapy?

Dapagliflozin is administered once daily. taken as a tablet (5 and 10 mg). “It is usable as an add-on combination therapy with other glucose-lowering medical agents (including insulin), and when these together with exercise and diet did not provide adequate glycemic control,” Prof. Bailey explained. “As monotherapy, it is used in metformin-intolerant patients in whom neither exercise nor diet produced sufficient effect.”

Clinical trial

A multicenter, placebo-controlled, randomized phase III trial and its extension to up to 102 weeks [2,3] showed the following benefits of treatment with dapagliflozin (as an add-on to metformin):

  • Significant and sustained HbA1c reduction
  • Sustained weight reduction
  • Low incidence of hypoglycemia
  • May also help control blood pressure
  • Is compatible with other diabetic therapies.

“Various phase III studies, some of which were presented at last year’s EASD congress, confirmed the (long-lasting) effect of dapagliflozin on HbA1c in type 2 diabetes mellitus, in various combinations (metformin, insulin). The efficacy here depends on whether renal function is normal or impaired: in type 2 patients with moderate renal impairment, dapagliflozin did not affect HbA1c, but continued to affect weight and blood pressure [4]. The effect on weight (reduction or at least stabilization) was confirmed in various phase III studies, in monotherapy, but also in combination with metformin, glimepiride, pioglitazone and insulin,” says Prof. Gottfried Rudofsky, MD, Kantonsspital Olten. “Dapagliflozin does not harm the kidney. Similarly, an increase in bladder and breast cancer incidences initially observed in clinical trials could not be confirmed. One concern, however, is urogenital infections, which are more common with dapagliflozin and have led (in part but rarely) to treatment discontinuation.”

Source: “SGLT2 Inhibition: Novel Oral Treatment Options for Type 2 Diabetes,” AstraZeneca Satellite Symposium at ESCIM Congress, May 14-16, 2014, Geneva.

Literature:

  1. Bailey CJ: Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011 Feb; 32(2): 63-71.
  2. Bailey CJ, et al: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010 Jun 26; 375(9733): 2223-2233.
  3. Bailey CJ, et al: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013 Feb 20; 11: 43.
  4. Kohan DE, et al: Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014 Apr; 85(4): 962-971.

CONGRESS SPECIAL 2014; 5(2): 25-26

Autoren
  • Andreas Grossmann
Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • Dapagliflozin
  • Diabetes
  • Glucose
  • Glucosuria
  • Hyperglycemia
  • Hypoglycemia
  • Monotherapy
  • Plasma glucose
  • SGLT-2 inhibitors
  • Sugar
Previous Article
  • Intracerebral hemorrhage and stroke

Nursing home residents do not benefit from occupational therapy after stroke

  • Cardiology
  • Congress Reports
  • Geriatrics
  • Neurology
  • Physical medicine and rehabilitation
  • RX
  • Studies
View Post
Next Article
  • Chronic renal failure, dialysis and kidney transplantation

“Diabesity – a new epidemic?

  • Congress Reports
  • Departments
  • Endocrinology and Diabetology
  • Nephrology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 5 min
  • Asthma in adults

When do pneumology specialists come into play?

    • RX
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.